Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | TP53 | P04637 | 4/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12162786 | 0.93 | MAPT (0.42) | MAPTTP53THRBALDH1A1SMN1; SMN2 | |
| SCHEMBL14047394 | 0.91 | MAPT (0.43) | MAPTTP53THRBALDH1A1SMN1; SMN2 | |
| SCHEMBL880286 | 0.82 | MAPT (0.56) | MAPTTP53THRBALDH1A1SMN1; SMN2 | |
| SCHEMBL880298 | 0.82 | ALDH1A1 (0.51) | MAPTTP53THRBALDH1A1KDM4E | |
| SCHEMBL14379521 | 0.71 | CA12 (0.49) | MAPTTP53ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL880429 | 0.68 | SMN1; SMN2 (0.64) | MAPTTP53ALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL13522455 | 0.67 | CYP19A1 (0.43) | ALDH1A1KDM4EMAPK1ALDH2CYP19A1 | |
| SCHEMBL28218523 | 0.65 | MAPT (0.41) | MAPTTP53THRBALDH1A1SMN1; SMN2 | |
| SCHEMBL7533164 | 0.63 | PLA2G6 (0.56) | MAPTTP53THRBALDH1A1SMN1; SMN2 | |
| SCHEMBL7086096 | 0.62 | HPGD (0.41) | MAPTALDH1A1MEN1KMT2AALDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004277-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004277-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | GOLT1B, NPC1L1, NPC1 | MAPT 640/4885TP53 3445/4885THRB 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.